Overview

Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD)

Status:
Not yet recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This is a phase 2 randomized, double -masked study comparing the efficacy of EYP-1901 at two dose levels: 2060 ug and 3090 ug against Aflibercept.
Phase:
Phase 2
Details
Lead Sponsor:
EyePoint Pharmaceuticals, Inc.
Treatments:
Aflibercept